Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14

Reuters03-18

Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14

Arvinas reported Phase 1 multiple-dose cohort data for ARV-102, an oral PROTAC designed to degrade LRRK2 in patients with Parkinson’s disease, and said the results were presented during an oral session at the AD/PD 2026 conference. In the trial, once-daily ARV-102 at 20 mg to 80 mg for 28 days reduced LRRK2 in cerebrospinal fluid by at least 50% by day 14 and maintained that reduction through day 28. Arvinas also reported reductions in endolysosomal and neuroinflammatory biomarkers including CD68 and GPNMB. The company said ARV-102 was generally well tolerated, with no serious adverse events reported after multiple doses. Arvinas said it intends to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, pending regulatory feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180700PRIMZONEFULLFEED9673882) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620237153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620237153","market":"nz","top_or_hot":-1,"title":"Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arvinas reported Phase 1 multiple-dose cohort data for ARV-102, an oral PROTAC designed to degrade LRRK2 in patients with Parkinson’s disease, and said the results were presented during an oral session at the AD/PD 2026 conference. In the trial, once-daily ARV-102 at 20 mg to 80 mg for 28 days reduced LRRK2 in cerebrospinal fluid by at least 50% by day 14 and maintained that reduction through day 28. Arvinas also reported reductions in endolysosomal and neuroinflammatory biomarkers including CD68 and GPNMB. The company said ARV-102 was generally well tolerated, with no serious adverse events reported after multiple doses. Arvinas said it intends to initiate a Phase 1b trial in progressive supranuclear palsy in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, pending regulatory feedback.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180700PRIMZONEFULLFEED9673882) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arvinas reported Phase 1 multiple-dose cohort data for ARV-102, an oral PROTAC designed to degrade LRRK2 in patients with Parkinson’s disease, and said the results were presented during an oral session at the AD/PD 2026 conference. In the trial, once-daily ARV-102 at 20 mg to 80 mg for 28 days reduced LRRK2 in cerebrospinal fluid by at least 50% by day 14 and maintained that reduction through day 28. Arvinas also reported reductions in endolysosomal and neuroinflammatory biomarkers including CD68 and GPNMB. The company said ARV-102 was generally well tolerated, with no serious adverse events reported after multiple doses. Arvinas said it intends to initiate a Phase 1b trial in progressive supranuclear palsy in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, pending regulatory feedback.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180700PRIMZONEFULLFEED9673882) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbQH1mn:1","article_id":"2620237153","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620237153","pubTimestamp":1773831886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arvinas reported Phase 1 multiple-dose cohort data for ARV-102, an oral PROTAC designed to degrade LRRK2 in patients with Parkinson’s disease, and said the results were presented during an oral session at the AD/PD 2026 conference. In the trial, once-daily ARV-102 at 20 mg to 80 mg for 28 days reduced LRRK2 in cerebrospinal fluid by at least 50% by day 14 and maintained that reduction through day 28. Arvinas also reported reductions in endolysosomal and neuroinflammatory biomarkers including CD68 and GPNMB. The company said ARV-102 was generally well tolerated, with no serious adverse events reported after multiple doses. Arvinas said it intends to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, pending regulatory feedback.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","ARVN":"Arvinas Holding Company LLC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4112":"金融交易所和数据","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4007":"制药"},"translate_title":"ARVINAS 1期试验显示ARV-102在第14天可使帕金森脑脊液中的LRRK2降低至少50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ARVN":0.9},"content_text":"Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14\n    \n\n        Arvinas reported Phase 1 multiple-dose cohort data for ARV-102, an oral PROTAC designed to degrade LRRK2 in patients with Parkinson’s disease, and said the results were presented during an oral session at the AD/PD 2026 conference. In the trial, once-daily ARV-102 at 20 mg to 80 mg for 28 days reduced LRRK2 in cerebrospinal fluid by at least 50% by day 14 and maintained that reduction through day 28. Arvinas also reported reductions in endolysosomal and neuroinflammatory biomarkers including CD68 and GPNMB. The company said ARV-102 was generally well tolerated, with no serious adverse events reported after multiple doses. Arvinas said it intends to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, pending regulatory feedback.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180700PRIMZONEFULLFEED9673882) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620237153","isCrawlerRequest":true}